These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

597 related items for PubMed ID: 26240221

  • 21. Racial differences in three major NHL subtypes: descriptive epidemiology.
    Li Y, Wang Y, Wang Z, Yi D, Ma S.
    Cancer Epidemiol; 2015 Feb; 39(1):8-13. PubMed ID: 25560974
    [Abstract] [Full Text] [Related]

  • 22. Risk and outcome of non-Hodgkin lymphoma among classical Hodgkin lymphoma survivors.
    Xavier AC, Armeson KE, Hill EG, Costa LJ.
    Cancer; 2013 Sep 15; 119(18):3385-92. PubMed ID: 23797978
    [Abstract] [Full Text] [Related]

  • 23. Contributions of Subtypes of Non-Hodgkin Lymphoma to Mortality Trends.
    Howlader N, Morton LM, Feuer EJ, Besson C, Engels EA.
    Cancer Epidemiol Biomarkers Prev; 2016 Jan 15; 25(1):174-9. PubMed ID: 26472423
    [Abstract] [Full Text] [Related]

  • 24. Incidence and epidemiology of non-Hodgkin lymphoma and risk of second malignancy among 22 466 survivors in Israel with 30 years of follow-up.
    Tadmor T, Liphshitz I, Silverman B, Polliack A.
    Hematol Oncol; 2017 Dec 15; 35(4):599-607. PubMed ID: 27238496
    [Abstract] [Full Text] [Related]

  • 25. Racial differences in the presentation and outcomes of chronic lymphocytic leukemia and variants in the United States.
    Shenoy PJ, Malik N, Sinha R, Nooka A, Nastoupil LJ, Smith M, Flowers CR.
    Clin Lymphoma Myeloma Leuk; 2011 Dec 15; 11(6):498-506. PubMed ID: 21889433
    [Abstract] [Full Text] [Related]

  • 26. Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study.
    Spanogle JP, Clarke CA, Aroner S, Swetter SM.
    J Am Acad Dermatol; 2010 May 15; 62(5):757-67. PubMed ID: 20223559
    [Abstract] [Full Text] [Related]

  • 27. Evidence for an association between cutaneous malignant melanoma and lymphoid malignancy: a population-based retrospective cohort study in Scotland.
    McKenna DB, Stockton D, Brewster DH, Doherty VR.
    Br J Cancer; 2003 Jan 13; 88(1):74-8. PubMed ID: 12556962
    [Abstract] [Full Text] [Related]

  • 28. The risk of melanoma in patients with chronic lymphocytic leukemia; a population-based study.
    Turk T, Saad AM, Al-Husseini MJ, Gad MM.
    Curr Probl Cancer; 2020 Apr 13; 44(2):100511. PubMed ID: 32115255
    [Abstract] [Full Text] [Related]

  • 29. Risk and survival of cutaneous melanoma diagnosed subsequent to a previous cancer.
    Yang GB, Barnholtz-Sloan JS, Chen Y, Bordeaux JS.
    Arch Dermatol; 2011 Dec 13; 147(12):1395-402. PubMed ID: 22184761
    [Abstract] [Full Text] [Related]

  • 30. Screening for second malignancies in mycosis fungoides: non-Hodgkin lymphoma, Hodgkin lymphoma, lung cancer, bladder cancer and melanoma.
    Goyal A, O'Leary D, Goyal K, Rubin N, Janakiram M.
    J Eur Acad Dermatol Venereol; 2021 Sep 13; 35(9):1821-1829. PubMed ID: 34013554
    [Abstract] [Full Text] [Related]

  • 31. Second cancers in patients with chronic lymphocytic leukemia.
    Travis LB, Curtis RE, Hankey BF, Fraumeni JF.
    J Natl Cancer Inst; 1992 Sep 16; 84(18):1422-7. PubMed ID: 1512794
    [Abstract] [Full Text] [Related]

  • 32. The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma.
    Tward JD, Wendland MM, Shrieve DC, Szabo A, Gaffney DK.
    Cancer; 2006 Jul 01; 107(1):108-15. PubMed ID: 16708354
    [Abstract] [Full Text] [Related]

  • 33. Relationship between ambient ultraviolet radiation and non-Hodgkin lymphoma subtypes: a U.S. population-based study of racial and ethnic groups.
    Cahoon EK, Pfeiffer RM, Wheeler DC, Arhancet J, Lin SW, Alexander BH, Linet MS, Freedman DM.
    Int J Cancer; 2015 Mar 01; 136(5):E432-41. PubMed ID: 25258118
    [Abstract] [Full Text] [Related]

  • 34. Non-Hodgkin's lymphomas, chronic lymphocytic leukaemias and skin cancers.
    Levi F, Randimbison L, Te VC, La Vecchia C.
    Br J Cancer; 1996 Dec 01; 74(11):1847-50. PubMed ID: 8956805
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Hormone replacement therapy and risk of non-hodgkin lymphoma and chronic lymphocytic leukemia.
    Cerhan JR, Vachon CM, Habermann TM, Ansell SM, Witzig TE, Kurtin PJ, Janney CA, Zheng W, Potter JD, Sellers TA, Folsom AR.
    Cancer Epidemiol Biomarkers Prev; 2002 Nov 01; 11(11):1466-71. PubMed ID: 12433728
    [Abstract] [Full Text] [Related]

  • 37. Subsequent malignancies among long-term survivors of Hodgkin lymphoma and non-Hodgkin lymphoma: a pooled analysis of German cancer registry data (1990-2012).
    Baras N, Dahm S, Haberland J, Janz M, Emrich K, Kraywinkel K, Salama A.
    Br J Haematol; 2017 Apr 01; 177(2):226-242. PubMed ID: 28106907
    [Abstract] [Full Text] [Related]

  • 38. Risk of second primary papillary thyroid cancer among adult cancer survivors in the United States, 2000-2015.
    Schonfeld SJ, Morton LM, Berrington de González A, Curtis RE, Kitahara CM.
    Cancer Epidemiol; 2020 Feb 01; 64():101664. PubMed ID: 31884334
    [Abstract] [Full Text] [Related]

  • 39. Increased risk of second primary cancers after a diagnosis of melanoma.
    Bradford PT, Freedman DM, Goldstein AM, Tucker MA.
    Arch Dermatol; 2010 Mar 01; 146(3):265-72. PubMed ID: 20231496
    [Abstract] [Full Text] [Related]

  • 40. A prospective analysis of circulating saturated and monounsaturated fatty acids and risk of non-Hodgkin lymphoma.
    Chiu YH, Bertrand KA, Zhang S, Laden F, Epstein MM, Rosner BA, Chiuve S, Campos H, Giovannucci EL, Chavarro JE, Birmann BM.
    Int J Cancer; 2018 Oct 15; 143(8):1914-1922. PubMed ID: 29756258
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 30.